


DIETER HAUSCHKE, VOLKER STEINIJANS  
and IRIS PIGEOT

# Bioequivalence Studies in Drug Development

Methods and Applications



 **WILEY**

**STATISTICS IN PRACTICE**

R914  
H376

# Bioequivalence Studies in Drug Development

## Methods and Applications

**Dieter Hauschke**

*Department of Biometry  
ALTANA Pharma, Germany*

**Volker Steinijans**

*Department of Biometry  
ALTANA Pharma, Germany*

**Iris Pigeot**

*Bremen Institute for Prevention Research and Social Medicine,  
University of Bremen, Germany*



John Wiley & Sons, Ltd



E2008000684

Copyright © 2007 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester,  
West Sussex PO19 8SQ, England

Telephone (+44) 1243 779777

Email (for orders and customer service enquiries): cs-books@wiley.co.uk

Visit our Home Page on [www.wiley.com](http://www.wiley.com)

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed to [permreq@wiley.co.uk](mailto:permreq@wiley.co.uk), or faxed to (+44) 1243 770620.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The Publisher is not associated with any product or vendor mentioned in this book.

This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the Publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

#### ***Other Wiley Editorial Offices***

John Wiley & Sons Inc., 111 River Street, Hoboken, NJ 07030, USA

Jossey-Bass, 989 Market Street, San Francisco, CA 94103-1741, USA

Wiley-VCH Verlag GmbH, Boschstr. 12, D-69469 Weinheim, Germany

John Wiley & Sons Australia Ltd, 42 McDougall Street, Milton, Queensland 4064, Australia

John Wiley & Sons (Asia) Pte Ltd, 2 Clementi Loop #02-01, Jin Xing Distripark, Singapore 129809

John Wiley & Sons Canada Ltd, 22 Worcester Road, Etobicoke, Ontario, Canada M9W 1L1

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

#### ***Library of Congress Cataloging in Publication Data***

Hauschke, Dieter.

Bioequivalence studies in drug development : methods and applications / Dieter Hauschke,  
Volker Steinijans, Iris Pigeot.

p. ; cm.

Includes bibliographical references and indexes.

ISBN-13: 978-0-470-09475-4 (HB : alk. paper)

ISBN-10: 0-470-09475-3 (HB : alk. paper)

1. Drugs—Therapeutic equivalency. I. Steinijans, Volker. II. Pigeot, Iris. III. Title. [DNLM:  
1. Therapeutic Equivalency. 2. Clinical Trials—methods. 3. Drug Design. QV 38 H376b 2007]  
RM301.45.H38 2007

615'.19—dc22

2006029953

#### ***British Library Cataloguing in Publication Data***

A catalogue record for this book is available from the British Library

ISBN-13: 978-0-470-09475-4 (HB)

ISBN-10: 0-470-09475-3 (HB : alk. paper)

Typeset in 10/12pt Times by Integra Software Services Pvt. Ltd, Pondicherry, India

Printed and bound in Great Britain by Antony Rowe Ltd, Chippenham, Wiltshire

This book is printed on acid-free paper responsibly manufactured from sustainable forestry in which at least two trees are planted for each one used for paper production.

# Bioequivalence Studies in Drug Development

# Statistics in Practice

*Advisory Editors*

**Stephen Senn**

University of Glasgow, UK

**Marian Scott**

University of Glasgow, UK

**Peter Bloomfield**

North Carolina State University, USA

*Founding Editor*

**Vic Barnett**

Nottingham Trent University, UK

---

*Statistics in Practice* is an important international series of texts which provide detailed coverage of statistical concepts, methods and worked case studies in specific fields of investigation and study.

With sound motivation and many worked practical examples, the books show in down-to-earth terms how to select and use an appropriate range of statistical techniques in a particular practical field within each title's special topic area.

The books provide statistical support for professionals and research workers across a range of employment fields and research environments. Subject areas covered include medicine and pharmaceuticals; industry, finance and commerce; public services; the earth and environmental sciences, and so on.

The books also provide support to students studying statistical courses applied to the above areas. The demand for graduates to be equipped for the work environment has led to such courses becoming increasingly prevalent at universities and colleges.

It is our aim to present judiciously chosen and well-written workbooks to meet everyday practical needs. Feedback of views from readers will be most valuable to monitor the success of this aim.

A complete list of titles in this series appears at the end of the volume.

*The book is for*

- my family, for their encouragement: Carmen, Simon, Andreas, Eva and Andi (Dieter Hauschke)*
- Helga, Eva and Uwe (Volker Steinijans)*
- my husband Jürgen and the BIPS, for their neverending patience (Iris Pigeot)*

# Preface

The design, performance, and evaluation of bioavailability and bioequivalence studies have received major attention from academia, the pharmaceutical industry and health authorities over the last couple of decades. Hence, the focus of the book is to provide an up-to-date overview of available methods, adopting a practical approach via numerous examples using real data. We also include recent methodology, most notably on the concepts of population and individual bioequivalence.

This book is a useful reference for clinical pharmacologists, biopharmaceutical scientists, reviewers from regulatory affairs, and biometricians working in the pharmaceutical industry. In addition, the presented material provides a springboard for all scientists from academia who are conducting research in this area of biopharmaceutics and clinical pharmacokinetics.

The book consists of 10 chapters, which cover planning, conduct, analysis, and reporting of bioequivalence studies according to current regulatory requirements. The methods are illustrated by a large number of real datasets. Moreover, the corresponding SAS<sup>®</sup> code is provided to assist the reader in implementing the analysis.

We are grateful to our colleagues Anton Drollmann, Christian Gartner, Kai Grosch, Dietrich Knoerzer, Olaf Michel, Rüdiger Nave, and Stephen Senn for comments on individual chapters, Martin Burke, Edgar Diletti, and Marc Suling for contributing SAS<sup>®</sup> code and generating the figures. We are also grateful for editorial help to Regine Albrecht, Elena Gamp, Beate Riedlinger, Rita Sauter, and Birgit Schroeder. At Wiley & Sons, we thank Wendy Hunter for providing continuous support during the production process.

Finally, we take responsibility for any errors in the book. Comments are most welcome for the preparation of further editions.

*Dieter Hauschke  
Volker Steinijans  
Iris Pigeot*

# Contents

<b>Preface</b>	<b>xiii</b>
<b>1 Introduction</b>	<b>1</b>
1.1 Definitions	1
1.1.1 Bioavailability	2
1.1.2 Bioequivalence	2
1.1.3 Therapeutic equivalence	3
1.2 When are bioequivalence studies performed	4
1.2.1 Applications for products containing new active substances	4
1.2.2 Applications for products containing approved active substances	4
1.2.3 Applications for modified release forms essentially similar to a marketed modified release form	4
1.3 Design and conduct of bioequivalence studies	5
1.3.1 Crossover design and alternatives	5
1.3.2 Single- vs. multiple-dose studies	6
1.3.3 Pharmacokinetic characteristics	6
1.3.4 Subjects	7
1.3.5 Statistical models	8
1.3.5.1 Average bioequivalence	8
1.3.5.2 Population bioequivalence	9
1.3.5.3 Individual bioequivalence	11
1.3.6 Sample size	12
1.4 Aims and structure of the book	14
References	15
<b>2 Metrics to characterize concentration-time profiles in single- and multiple-dose bioequivalence studies</b>	<b>17</b>
2.1 Introduction	17
2.2 Pharmacokinetic characteristics (metrics) for single-dose studies	20
2.2.1 Extent of bioavailability	20
2.2.2 Rate of bioavailability	24



2.3	Pharmacokinetic rate and extent characteristics (metrics) for multiple-dose studies .....	26
2.4	Conclusions .....	34
	References .....	34
<b>3</b>	<b>Basic statistical considerations</b>	<b>37</b>
3.1	Introduction .....	37
3.2	Additive and multiplicative model .....	38
3.2.1	The normal distribution .....	38
3.2.2	The lognormal distribution .....	41
3.3	Hypotheses testing .....	44
3.3.1	Consumer and producer risk .....	44
3.3.2	Types of hypotheses .....	46
3.3.2.1	Test for difference .....	47
3.3.2.2	Test for superiority .....	47
3.3.2.3	Test for noninferiority .....	48
3.3.2.4	Test for equivalence .....	49
3.3.3	Difference versus ratio of expected means .....	51
3.3.3.1	The normal distribution .....	51
3.3.3.2	The lognormal distribution .....	53
3.4	The <i>RT/TR</i> crossover design assuming an additive model .....	55
3.4.1	Additive model and effects .....	55
3.4.2	Parametric analysis based on <i>t</i> -tests .....	56
3.4.2.1	Test for difference in carryover effects .....	59
3.4.2.2	Test for difference in formulation effects .....	60
3.4.2.3	Test for difference in period effects .....	63
3.4.3	Nonparametric analysis based on Wilcoxon rank sum tests .....	65
3.4.3.1	Test for difference in carryover effects .....	65
3.4.3.2	Test for difference in formulation effects .....	66
3.4.3.3	Test for difference in period effects .....	67
	References .....	68
<b>4</b>	<b>Assessment of average bioequivalence in the <i>RT/TR</i> design</b>	<b>69</b>
4.1	Introduction .....	69
4.2	The <i>RT/TR</i> crossover design assuming a multiplicative model .....	72
4.2.1	Multiplicative model and effects .....	73
4.2.2	Test problem .....	75
4.2.3	Estimation of the formulation difference .....	77
4.3	Test procedures for bioequivalence assessment .....	80
4.3.1	Analysis of variance .....	80
4.3.1.1	Example: Dose equivalence study .....	84
4.3.2	Two one-sided <i>t</i> -tests and $(1 - 2\alpha)100\%$ confidence interval ...	89
4.3.2.1	Example: Dose equivalence study .....	91
4.3.3	Two one-sided Wilcoxon rank sum tests and $(1 - 2\alpha)100\%$ confidence interval .....	94

4.3.3.1	Example: Dose equivalence study .....	96
4.3.3.2	Analysis of time to maximum concentration .....	97
4.3.4	Bioequivalence ranges .....	101
4.4	Conclusions .....	103
	References .....	103
<b>5</b>	<b>Power and sample size determination for testing average bioequivalence in the <i>RT/TR</i> design</b> .....	<b>105</b>
5.1	Introduction .....	105
5.2	Challenging the classical approach .....	106
5.3	Exact power and sample size calculation .....	109
5.4	Modified acceptance ranges .....	112
5.5	Approximate formulas for sample size calculation .....	114
5.6	Exact power and sample size calculation by nQuery® .....	117
	Appendix .....	120
	References .....	121
<b>6</b>	<b>Presentation of bioequivalence studies</b> .....	<b>123</b>
6.1	Introduction .....	123
6.2	Results from a single-dose study .....	124
6.3	Results from a multiple-dose study .....	140
6.4	Conclusions .....	152
	References .....	154
<b>7</b>	<b>Designs with more than two formulations</b> .....	<b>157</b>
7.1	Introduction .....	157
7.2	Williams designs .....	158
7.3	Example: Dose linearity study .....	159
7.4	Multiplicity .....	161
7.4.1	Joint decision rule .....	165
7.4.2	Multiple decision rule .....	171
7.5	Conclusions .....	172
	References .....	172
<b>8</b>	<b>Analysis of pharmacokinetic interactions</b> .....	<b>175</b>
8.1	Introduction .....	175
8.2	Pharmacokinetic drug–drug interaction studies .....	178
8.2.1	Absorption .....	178
8.2.2	Distribution .....	178
8.2.3	Elimination .....	178
8.2.3.1	Metabolism .....	179
8.2.3.1.1	Metabolic induction .....	179
8.2.3.1.2	Metabolic inhibition .....	181
8.2.3.1.3	Change of blood flow .....	182

8.2.3.2	Renal excretion .....	182
8.2.3.3	Hepatic/biliary excretion.....	183
8.2.4	Experimental design of <i>in vivo</i> drug–drug interaction studies...	183
8.2.5	Examples to illustrate drug–drug interactions and the lack thereof .....	184
8.2.6	Pharmacokinetic characteristics for extent of absorption and clearance in drug–drug interaction studies .....	187
8.2.6.1	Theoretical background on <i>AUC</i> as a composite measure of absorption and clearance .....	190
8.2.6.2	Examples to illustrate the composite character of <i>AUC</i> .....	192
8.2.6.3	Recommendation for subsequent analyses .....	193
8.3	Pharmacokinetic food–drug interactions.....	194
8.3.1	Classification of food effects .....	194
8.3.2	Experimental design of food–drug interaction studies.....	196
8.3.3	Example: Theophylline food interaction study .....	197
8.4	Goal posts for pharmacokinetic drug interaction studies including no effect boundaries.....	197
8.5	Labeling .....	199
8.6	Conclusions .....	200
	References .....	200
<b>9</b>	<b>Population and individual bioequivalence</b>	<b>205</b>
9.1	Introduction .....	205
9.2	Brief history .....	208
9.3	Study designs and statistical models .....	210
9.3.1	Classical two-period, two-sequence crossover design .....	210
9.3.2	Replicate designs.....	210
9.3.3	Additive model.....	212
9.3.4	Basic concepts of aggregate measures .....	213
9.3.5	Example: The antihypertensive patch dataset.....	215
9.4	Population bioequivalence .....	217
9.4.1	Moment-based criteria .....	217
9.4.1.1	Statistical procedures .....	219
9.4.1.1.1	The bootstrap procedure .....	219
9.4.1.1.2	A parametric confidence interval .....	220
9.4.2	Probability-based criteria.....	225
9.4.2.1	Statistical procedures .....	225
9.4.2.1.1	A distribution-free approach.....	225
9.4.2.1.2	A parametric approach.....	228
9.5	Individual bioequivalence.....	230
9.5.1	Moment-based criteria .....	230
9.5.1.1	Statistical procedures .....	232
9.5.1.1.1	The bootstrap procedure .....	232
9.5.1.1.2	A parametric confidence interval .....	233

9.5.2	Probability-based criteria .....	236
9.5.2.1	Statistical procedures .....	236
9.5.2.1.1	A distribution-free approach .....	237
9.5.2.1.2	A parametric approach .....	239
9.5.2.1.3	Test for individual equivalence ratio (TIER) .....	241
9.5.3	Relationships between aggregate bioequivalence criteria ....	243
9.5.4	Drawbacks of aggregate measures .....	245
9.6	Disaggregate criteria .....	246
9.6.1	Stepwise procedure on the original scale .....	246
9.6.2	Stepwise procedure on the logarithmic scale .....	253
9.7	Other approaches .....	255
9.7.1	Trimmed Mallows distance .....	255
9.7.2	Kullback–Leibler divergence .....	256
9.7.3	Structural equation model .....	257
9.8	Average bioequivalence in replicate designs .....	258
9.9	Example: The antihypertensive patch dataset .....	259
9.10	Conclusions .....	278
	References .....	280
<b>10</b>	<b>Equivalence assessment for clinical endpoints</b> .....	<b>283</b>
10.1	Introduction .....	283
10.2	Design and testing procedure .....	285
10.2.1	Parallel group design .....	285
10.2.2	Crossover design .....	287
10.3	Power and sample size calculation .....	289
10.3.1	Parallel group design .....	289
10.3.2	Crossover design .....	292
10.3.3	Approximate formulas for sample size calculation .....	297
10.3.4	Exact power and sample size calculation by nQuery® .....	302
10.4	Conclusions .....	303
	Appendix .....	304
	References .....	305
<b>Index</b>		<b>307</b>

# Introduction

Comparison of therapeutic performance of two medicinal products containing the same active substance is critical for assessing the possibility of supplanting an innovator with any essentially similar medicinal product. In practice, demonstration of bioequivalence is generally the most appropriate method of substantiating therapeutic equivalence between medicinal products. Assuming that, in the same subject, similar plasma concentration-time courses will result in similar concentrations at the site of action and thus in similar effects, pharmacokinetic data instead of therapeutic results may be used to demonstrate bioequivalence as an established surrogate marker for therapeutic equivalence.

The design, performance and evaluation of bioequivalence studies have received major attention from academia, the pharmaceutical industry and health authorities over the last couple of decades. Since 2003 there has been international consensus and current regulatory guidelines (Committee for Proprietary Medicinal Products (CPMP), 2001; Food and Drug Administration (FDA), 2003) require the demonstration of average bioequivalence between a test and a reference formulation, which means equivalence with regard to the population means.

The purpose of this chapter is to provide some essential features of bioequivalence trials. In particular we shall

- give the underlying definitions;
- explain when bioequivalence studies are performed;
- refer to the design and conduct of these studies.

## 1.1 Definitions

Although the beginning of the search for bioequivalence standards dates back to the early 1970s, there is no International Conference on Harmonization (ICH) Guidance on

bioavailability and bioequivalence. Thus, the definitions given in the following primarily reflect the current guidelines of the US Food and Drug Administration and the European Committee for Proprietary Medicinal Products (FDA, 2003; CPMP, 2001). However, in order to illustrate how these concepts developed, other definitions are also cited.

### **1.1.1 Bioavailability**

In the 2003 FDA guidance,

‘Bioavailability is defined as the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.’

This definition focuses on the processes by which the active ingredients or moieties are released from an oral dosage form and move to the site of action. Such processes may also be influenced by drug properties such as permeability and the influences of presystemic enzymes and/or active transporters (e.g., p-glycoprotein).

To avoid an inconsistent use of the term ‘absorption’, Chiou (2001) suggested that absorption be defined as movement of drug across the outer mucosal membranes of the GI tract, while bioavailability be defined as availability of drug to the general circulation or site of pharmacological actions.

### **1.1.2 Bioequivalence**

One of the operationally most feasible definitions of bioequivalence was given at the BIO-International ‘94 Conference in Munich (Skelly, 1995),

‘Two pharmaceutical products are considered to be equivalent when their concentration vs. time profiles, from the same molar dose, are so similar that they are unlikely to produce clinically relevant differences in therapeutic and/or adverse effects.’

It is this definition that comes closest to the operational procedure of comparing concentration-time profiles, or suitable metrics characterizing such profiles, in order to assess bioequivalence.

However, this practical definition was not adopted in the 2001 CPMP guidance on bioavailability and bioequivalence, which hardly changed its previous 1991 definition (CPMP, 2001),

‘Two medicinal products are bioequivalent if they are pharmaceutically equivalent or pharmaceutical alternatives and if their bioavailabilities after administration in the same molar dose are similar to such a degree that their effects, with respect to both efficacy and safety, will be essentially the same.’

The definition of pharmaceutical equivalents and alternatives is given as,

‘Medicinal products are pharmaceutically equivalent if they contain the same amount of the same active substance(s) in the same dosage forms that meet

the same or comparable standards. They are pharmaceutical alternatives if they contain the same active moiety but differ in chemical form (salt, ester, etc.) of that moiety, or in the dosage form or strength. It is well known that pharmaceutical equivalence does not necessarily imply bioequivalence as differences in the excipients and/or the manufacturing process can lead to faster or slower dissolution and/or absorption.'

Although the 2001 CPMP definition of bioequivalence addresses both similar efficacy, and similar safety, it should be noted that it is virtually impossible to conclude similar safety on the basis of a bioequivalence study with its limited number of subjects and limited exposure time. The conjecture appears to be that similarity of the concentration-time profiles, in particular similarity of the maximum concentrations, may serve as a surrogate marker for the similarity of the adverse event profiles to be anticipated.

In the 2003 FDA guidance,

'Bioequivalence is defined as the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.'

The FDA definition explicitly mentions rate and extent of drug availability as the two primary characteristics of the concentration-time profile. It is this concept of similarity in rate and extent of drug absorption which continues to define the bioequivalence metrics for rate and extent, and thereby the basis of the bioequivalence assessment.

It is interesting to note that there were various attempts to move away from this initial concept of rate and extent of drug absorption, particularly as some of the traditional rate characteristics such as  $C_{max}$  were identified as rather indirect, and frequently poor, measures of the true absorption rate. Steinijs *et al.* (1995a, 1996) proposed that bioequivalence assessment should focus on shape analysis of the concentration-time curves rather than on absorption rates. Chen *et al.* (2001) presented the concept of early, peak and total exposure, which at that time was under examination by the FDA. However, none of these alternative concepts were directly reflected in the corresponding guidelines.

### 1.1.3 Therapeutic equivalence

The 2001 CPMP guidance on bioavailability and bioequivalence also addresses the concept of therapeutic equivalence,

'A medicinal product is therapeutically equivalent with another product if it contains the same active substance or therapeutic moiety and, clinically, shows the same efficacy and safety as that product, whose efficacy and safety has been established. In practice, demonstration of bioequivalence is generally the most appropriate method of substantiating therapeutic equivalence between medicinal products, which are pharmaceutically equivalent or pharmaceutical alternatives, provided they contain excipients generally

recognized as not having an influence on safety and efficacy and comply with labeling requirements with respect to excipients. However, in some cases where similar extent of absorption but different rates of absorption are observed the products can still be judged therapeutically equivalent if those differences are not of therapeutic relevance. A clinical study to prove that differences in absorption rate are not therapeutically relevant will probably be necessary.'

## **1.2 When are bioequivalence studies performed**

### **1.2.1 Applications for products containing new active substances**

During the development of a new active substance (new chemical entity) intended for systemic action, bioequivalence studies are necessary as bridging studies between (i) pivotal and early clinical trial formulations; (ii) pivotal clinical trial formulations, especially those used in the dose finding studies, and the to-be-marketed medicinal product.

### **1.2.2 Applications for products containing approved active substances**

*In vivo* bioequivalence studies are needed when there is a risk that possible differences in bioavailability may result in therapeutic inequivalence. The CPMP guidance (2001) devotes an entire section to the necessity of bioequivalence studies for various dosage forms, taking into consideration the concepts underlying the Biopharmaceutics Classification System (Amidon *et al.*, 1995), i.e., high solubility, high permeability for the active substance, and high dissolution rate for the medicinal product. This section also addresses special topics such as

- Exemptions from bioequivalence studies in the case of oral immediate release forms (*in vitro* dissolution data as part of a bioequivalence waiver).
- Post approval changes.
- Dose proportionality of immediate release oral dosage forms (bioequivalence assessment for only one dose strength).
- Suprabioavailability (which necessitates reformulation to a lower dosage strength, otherwise the suprabioavailable product may be considered as new medicinal product, the efficacy and safety of which have to be supported by clinical studies).

### **1.2.3 Applications for modified release forms essentially similar to a marketed modified release form**

The requirements for modified release forms are stated in the CPMP Note for Guidance on Modified Release Oral and Transdermal Dosage Forms (1999), which differentiates between prolonged, delayed and transdermal release forms.



Prolonged release formulations can be assessed as bioequivalent on the basis of single-dose and multiple-dose studies, which are designed to demonstrate that

- The test formulation exhibits the claimed prolonged release characteristics of the reference.
- The active drug substance is not released unexpectedly from the test formulation (dose dumping).
- Performance of the test and reference formulation is equivalent after single dose and at steady state.
- The effect of food on the *in vivo* performance is comparable for both formulations when a single-dose study is conducted comparing equal doses of the test formulation with those of the reference formulation administered immediately after a predefined high fat meal. This study should be conducted with the same strength(s) as those of the pivotal bioequivalence studies.

In the case of prolonged release single unit formulations with multiple strengths, a single-dose study under fasting conditions is required for each strength. Studies at steady state may be conducted with the highest strength only, if certain criteria for extrapolating bioequivalence studies (linear pharmacokinetics, same qualitative composition, etc.) are fulfilled. For multiple unit formulations of a medicinal product showing linear pharmacokinetics with multiple strengths, a single-dose study under fasting conditions on the highest strength is sufficient, provided that the compositions of the lower strengths are proportional to that of the highest strength, the formulations contain identical beads or pellets, and the dissolution profiles are acceptable.

For delayed release formulations, postprandial bioequivalence studies are necessary as food can influence the absorption of an active substance administered in an enteric-coated formulation.

The bioequivalence of a transdermal drug delivery system (TDDS) in comparison to the innovator's product should usually be assessed after single dose as well as after multiple dose administration. When marketing authorization of multiple strengths is required, the bioequivalence study can be performed with the highest dosage strength provided that exact proportionality in the formulation is given, i.e., the composition is the same, and the strength is proportional to the effective surface area of the patch, and that there is an acceptable *in vitro* release test (CPMP, 1999).

## 1.3 Design and conduct of bioequivalence studies

### 1.3.1 Crossover design and alternatives

A bioequivalence study should be designed in such a way that the formulation effect can be distinguished from other effects. In the standard situation of comparing a test formulation (*T*) with a reference formulation (*R*), the two-period, two-sequence crossover design is the *RT/TR* design. Subjects are randomly allocated to two treatment sequences; in sequence 1, subjects receive the reference formulation and test formulation in periods